ArticleEndocrine2026
Pre- and post-operative metabolic profile of patients with pheochromocytoma: A retrospective multicenter study.
Article in Endocrine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo evaluate the metabolic dysregulation of patients with pheochromocytoma and their metabolic evolution after tumor resection.
methodsThis multicenter, retrospective study included individuals diagnosed and treated for pheochromocytoma at four Greek tertiary hospitals over the past twenty-five years. Clinical data were collected from medical records and compared according to catecholamine phenotypes, incidentaloma diagnosis and hypertensive status. Correlation analysis was performed between metabolic and pheochromocytoma-related characteristics. The evolution of metabolic profiles was assessed before and after adrenalectomy.
resultsA total of 117 patients were included (median age 51 years, 59.0% female). At diagnosis, the prevalence of diabetes/prediabetes, dyslipidemia and obesity was 58.1%, 65.0% and 19.7%, respectively. Adrenergic phenotype was predominant in older individuals (p = 0.004) and required significantly higher daily doses of phenoxybenzamine (p = 0.01). Metabolic and tumor parameters did not differ between catecholamine phenotypes. Patients with incidentalomas exhibited a higher prevalence of diabetes in comparison to their non-incidentaloma counterparts (p = 0.03), while the lipid profile did not differ between groups. Hypertensive patients had larger tumors (p = 0.01) with higher PASS (p = 0.012). Ninety-three patients were followed-up after adrenalectomy for a median period of 24 months. Postoperatively, the prevalence of hypertension and diabetes decreased with significant improvements in serum HbA1c, fasting glucose, cholesterol and LDL levels, despite no significant change in body mass index (BMI).
conclusionPheochromocytomas were associated with a high cardiometabolic burden. Metabolic profiles did not differ between catecholamine phenotypes, while adrenalectomy led to significant improvements in metabolic parameters despite stable BMI.
Indexed as
Identifiers
42440210What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.